MHC.GB MyHealthChecked Plc

TIDMMHC

RNS Number : 3215Z

MyHealthChecked PLC

11 January 2024

MyHealthChecked PLC

( " MyHealthChecked " or the "Company " )

Trading Update

Strong cash position of GBP7.75m

Traded profitably in H2 driven by COVID volume sales

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, provides an update on trading for the year ended 31 December 2023. The financial information is based on unaudited management accounts.

The Board is pleased to announce that MyHealthChecked has traded profitably during the second half of the year, whilst continuing to invest in the development of the new product range. The Board is expecting EBITDA for the full year to be around breakeven after adjusting for exceptional, non-recurring costs of cGBP0.1m (H1: GBP0.3m loss; FY 2022: GBP2.3m profit). Revenue for the full year amounted to approximately GBP11m (H1: GBP2.5m, 2022 FY: GBP22.3m) due to the increased seasonal demand for COVID lateral flow tests ("LFTs") during H2 which continue to account for the majority of revenue. As the working capital requirement has been carefully managed cash at the year-end has also increased to GBP7.75m (H1: GBP5.0m, FY 2022: GBP7.61m).

In May 2023 the Company announced the launch of its line of at-home wellness tests via boots.com and across Boots stores in Great Britain and Northern Ireland. There has been traction with the portfolio of tests which is encouraging at this early stage, and MyHealthChecked continues to improve its recommendation engine and digital platform, which is used to communicate with its at-home wellness test customers. The Company's strong cash position will enable it to deliver further developments and improvements from its own cash funds.

Penny McCormick, Chief Executive Officer of MyHealthChecked PLC , said: "The MyHealthChecked team worked incredibly hard to deliver our at-home wellness test portfolio in May last year. We invested significantly in digital resource during the year to ensure the critical launch timelines were met in launching this new category and enter 2024 with a streamlined development runway which will be delivered in accordance with the standards of ISO 27001, the international standard for information security.

Our performance in delivering COVID tests in 2023 has been strong. Whilst revenue has, as expected, reduced compared to the prior year, the seasonality of respiratory infections drove an uplift in demand during the second half, and we expect that COVID testing will remain an ongoing annual requirement for customers. Our aim for 2024 is to deliver positively on the investments that have been made so far, while we continue to develop and improve our digital platform. I am incredibly pleased with the progress that has been made to date."

For further information contact:

 
 MyHealthChecked plc                                                         www.myhealthchecked.com 
 P enny McCormick, Chief Executive                                                   via Walbrook PR 
  Officer 
 
 SPARK Advisory Partners Limited                                            Tel: +44 (0)20 3368 3550 
  (NOMAD) 
 Neil Baldwin / Jade Bayat 
 
 Dowgate Capital Limited (Broker)                                           Tel: +44 (0)20 3903 7715 
 David Poutney / Nicholas Chambers 
 
 Walbrook PR Ltd (Media                Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com 
  & IR) 
 Alice Woodings                                                              Mob: +44(0)7407 804 654 
 
 

About MyHealthChecked PLC ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTSFWEESELSEEF

(END) Dow Jones Newswires

January 11, 2024 02:00 ET (07:00 GMT)

MyHealthChecked (AQSE:MHC.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

MyHealthChecked (AQSE:MHC.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024